Title: GH Research Updates Clinical Development Program for GH001 in Treatment-Resistant Depression
Summary: GH Research PLC, a clinical-stage biopharmaceutical company, provides updates and guidance on its clinical development program for GH001, an inhalable mebufotenin product candidate, in the treatment of treatment-resistant depression (TRD). The company announced its development strategy and provided updates on its European Phase 2b clinical trial and the Investigational New Drug Application (IND) for GH001.
Headings:
– Development Strategy
– Update and Guidance on European Phase 2b Clinical Trial
– Update on IND for GH001
– About GH Research PLC
– About GH001
– About GH002 and GH003
– Forward-Looking Statements
